(Q46980731)

27 December 2017

title

M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis (English)

1 reference

27 December 2017

1 reference

1

1 reference

27 December 2017

Ugo Testa

12

1 reference

27 December 2017

Robin Foà

10

object named as

Robin Foà

1 reference

27 December 2017

9

Francesco Lo-Coco

1 reference

27 December 2017

Mara Senese

2

1 reference

27 December 2017

Daniela Diverio

3

1 reference

27 December 2017

Viviana Riti

4

1 reference

27 December 2017

Sonia Buffolino

5

1 reference

27 December 2017

Gualtiero Mariani

6

1 reference

27 December 2017

Alessandra Boe

7

1 reference

27 December 2017

Michele Cedrone

8

1 reference

27 December 2017

Cesare Peschle

11

1 reference

27 December 2017

language of work or name

English

0 references

publication date

1 October 2007

1 reference

27 December 2017

British Journal of Haematology

published in

1 reference

27 December 2017

volume

139

1 reference

27 December 2017

issue

2

1 reference

27 December 2017

page(s)

194-205

1 reference

27 December 2017

The development of proteasome inhibitors as anticancer drugs

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06757.X

The proteasome: a suitable antineoplastic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06757.X

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06757.X

Phase I study of bortezomib in refractory or relapsed acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06757.X

Acute myeloid leukemia: epidemiology and etiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06757.X

CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06757.X

Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06757.X

Preferential induction of apoptosis for primary human leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06757.X

Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06757.X

The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06757.X

An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06757.X

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06757.X

Abnormally high expression of proteasomes in human leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06757.X

The ubiquitin-proteasome pathway and its role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06757.X

Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06757.X

Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06757.X

Proteasome inhibitors: antitumor effects and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06757.X

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06757.X

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06757.X

Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06757.X

Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06757.X

The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06757.X

The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06757.X

Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06757.X

Proteasome inhibition as novel treatment strategy in leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06757.X

10.1111/J.1365-2141.2007.06757.X

21 January 2018

Identifiers

DOI

1 reference

27 December 2017

1 reference

27 December 2017